- Home
- ICG vs GLSI Comparison
ICG vs GLSI Comparison
Compare ICG & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICG
- GLSI
- Stock Information
- Founded
- ICG 2017
- GLSI 2006
- Country
- ICG China
- GLSI United States
- Employees
- ICG N/A
- GLSI N/A
- Industry
- ICG Semiconductors
- GLSI Biotechnology: Pharmaceutical Preparations
- Sector
- ICG Technology
- GLSI Health Care
- Exchange
- ICG Nasdaq
- GLSI Nasdaq
- Market Cap
- ICG 124.7M
- GLSI 133.4M
- IPO Year
- ICG 2023
- GLSI 2020
- Fundamental
- Price
- ICG $1.19
- GLSI $8.90
- Analyst Decision
- ICG Strong Buy
- GLSI Strong Buy
- Analyst Count
- ICG 2
- GLSI 1
- Target Price
- ICG $9.25
- GLSI $39.00
- AVG Volume (30 Days)
- ICG 83.2K
- GLSI 33.7K
- Earning Date
- ICG 08-14-2025
- GLSI 08-13-2025
- Dividend Yield
- ICG N/A
- GLSI N/A
- EPS Growth
- ICG N/A
- GLSI N/A
- EPS
- ICG 0.07
- GLSI N/A
- Revenue
- ICG $53,729,346.00
- GLSI N/A
- Revenue This Year
- ICG N/A
- GLSI N/A
- Revenue Next Year
- ICG $141.94
- GLSI N/A
- P/E Ratio
- ICG $16.04
- GLSI N/A
- Revenue Growth
- ICG 384.54
- GLSI N/A
- 52 Week Low
- ICG $1.19
- GLSI $8.06
- 52 Week High
- ICG $12.04
- GLSI $18.15
- Technical
- Relative Strength Index (RSI)
- ICG 23.40
- GLSI 35.87
- Support Level
- ICG $1.67
- GLSI $9.40
- Resistance Level
- ICG $2.20
- GLSI $9.92
- Average True Range (ATR)
- ICG 0.19
- GLSI 0.29
- MACD
- ICG -0.07
- GLSI -0.07
- Stochastic Oscillator
- ICG 0.00
- GLSI 0.00
About ICG Intchains Group Limited
Intchains Group Ltd provides integrated solutions consisting of high-performance ASIC chips and ancillary software and hardware for blockchain applications. Its ASIC chips are designed for several key blockchain algorithms including Blake2bsha3, sha512MD160, Cryptonight V4, Eaglesong, Blake2s and others. The company has built a proprietary technology platform named Xihe Platform, which allows the development of a wide range of ASIC chips with high efficiency and scalability. It designs its ASIC chips in-house, which enables it to leverage proprietary silicon data to deliver products reflecting the latest technological developments. Geographically, it operates in Mainland China, Hong Kong, and Other countries or regions.
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.